Dr. Paika Podcast

#Ozempic #Wegovy #GLP1 #WeightLoss #obesitymedicine 

Nausea, constipation, bloating, gas — if you're on semaglutide (Ozempic or Wegovy), gastrointestinal side effects are the most common thing you'll run into. In this video, I break down exactly why they happen and the specific, evidence-based strategies that actually reduce them: portion sizes, meal timing, which foods make it worse, hydration, injection timing, dose titration, and the red flags that mean it's time to call your doctor — not internet folklore, actual clinical data and two decades of hospital medicine.

🎓 Complete GLP-1 Weight Loss Masterclass — Lifetime Access
Comprehensive education on GLP-1 medications, nutrition, exercise, muscle preservation, side effects & long-term success. Includes the companion eBook, quizzes, 12-week exercise program, certificate & future course updates at no additional cost.
https://www.drmohammedpaika.com

📩 FREE GLP-1 Diet Cookbook + Weekly Newsletter
Get weekly evidence-based insights on GLP-1s, metabolic health, nutrition, exercise & longevity.
https://www.drmohammedpaika.com/newsletter

📚 The Weight Equation & The Physician’s Physique
Physician-written, evidence-based guides to obesity, weight loss, nutrition, metabolism, exercise, body composition & healthier living.
https://www.drmohammedpaika.com/books

👥 Metabolic Health Community
Live Q&As, evidence-based education, accountability, workouts, nutrition guidance & community support.
https://www.skool.com/metabolic-health-community-5316

TIMESTAMPS
0:00 – Intro & Disclaimer
1:35 – What Semaglutide Actually Is (and Why Side Effects Happen)
3:22 – Tip 1: Cut Your Portions
5:14 – Tip 2: Smaller, More Frequent Meals
6:27 – Tip 3: Foods That Work Against You
8:04 – Tip 4: Hydration & Constipation
9:04 – Tip 5: Time Your Injection Around Your Life
9:45 – Tip 6: Injection Site — Myth vs. Evidence
11:38 – Tip 7: Titration Schedule
12:34 – The Symptom Timeline: When It Gets Better
13:35 – When to Call Your Doctor
14:39 – The Bigger Picture
16:01 – Resources & Next Steps

Wilding JPH, Batterham RL, Calanna S, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine. 2021;384:989-1002. — https://www.nejm.org/doi/full/10.1056/NEJMoa2032183
Wharton S, Davies M, Dicker D, Lingvay I, Mosenzon O, Rubino DM, Pedersen SD. Managing the gastrointestinal side effects of GLP-1 receptor agonists in obesity: recommendations for clinical practice. Postgraduate Medicine. 2022;134(1):14-19. — https://www.tandfonline.com/doi/full/10.1080/00325481.2021.2002616
Mozaffarian D, et al. Nutritional priorities to support GLP-1 therapy for obesity: a joint Advisory from the American College of Lifestyle Medicine, the American Society for Nutrition, the Obesity Medicine Association, and The Obesity Society. Obesity. 2025. — https://ajcn.nutrition.org/article/S0002-9165(25)00240-0/fulltext
Saha B, Kamalumpundi V, Codipilly DC. GLP1 and GIP Receptor Agonists: Effects on the Gastrointestinal Tract and Management Strategies for Primary Care Physicians. Mayo Clinic Proceedings. 2025. — https://www.mayoclinicproceedings.org/article/S0025-6196(25)00551-8/fulltext
Novo Nordisk. Ozempic (semaglutide) injection Prescribing Information. — https://www.novo-pi.com/ozempic.pdf
Novo Nordisk. Wegovy (semaglutide) injection Prescribing Information. — https://www.novo-pi.com/wegovy.pdf
FDA Clinical Pharmacology Review, NDA 215866 (tirzepatide) — injection site bioequivalence data, cited in the corrected Tip 6. — https://www.accessdata.fda.gov/drugsatfda_docs/nda/2022/215866Orig1s000ClinPharmR.pdf

⚕️ MEDICAL & EDUCATIONAL DISCLAIMER
This channel and its content are provided by Dr. Mohammed K. Paika, MD for general educational and informational purposes only. The information presented is not intended as medical advice and does not replace consultation with your personal physician or qualified healthcare professional.
Viewing this content does not create a doctor-patient relationship between you and Dr. Paika.
Health, nutrition, exercise, and medication topics discussed on this channel may not be appropriate for all individuals. Always consult your own healthcare provider before starting or changing any medication, diet, exercise program, or weight-loss plan, including GLP-1 therapies such as Wegovy, Ozempic, Zepbound, Mounjaro, or similar medications.
Exercise and lifestyle changes carry inherent risks. By choosing to follow any information from this channel, you accept full responsibility for your health decisions and outcomes.
Dr. Paika and affiliated entities disclaim any liability for injuries, adverse effects, or damages resulting from use or application of information presented in this content.

#GLP1 #Ozempic #WeightLossJourney #ObesityMedicine #healthyeating 

Eating less on Ozempic, Wegovy, Mounjaro, or Zepbound doesn't automatically mean your diet is helping you lose fat. In this video, I break down the best foods to eat on a GLP-1 — protein, carbs, healthy fats, and fiber — so you preserve muscle, manage side effects, and get better results from your medication.

I'm Dr. Mohammed Paika, a board-certified internal medicine and obesity medicine physician. Everything in this video comes from the same nutrition science I use with real patients, including two cases straight from my hospital work.

🎓 Complete GLP-1 Weight Loss Masterclass — Lifetime Access
Comprehensive education on GLP-1 medications, nutrition, exercise, muscle preservation, side effects & long-term success. Includes the companion eBook, quizzes, 12-week exercise program, certificate & future course updates at no additional cost.
https://www.drmohammedpaika.com

📩 FREE GLP-1 Diet Cookbook + Weekly Newsletter
Get weekly evidence-based insights on GLP-1s, metabolic health, nutrition, exercise & longevity.
https://www.drmohammedpaika.com/newsletter

📚 The Weight Equation & The Physician’s Physique
Physician-written, evidence-based guides to obesity, weight loss, nutrition, metabolism, exercise, body composition & healthier living.
https://www.drmohammedpaika.com/books

👥 Metabolic Health Community
Live Q&As, evidence-based education, accountability, workouts, nutrition guidance & community support.
https://www.skool.com/metabolic-health-community-5316

TImestamps
0:00 Introduction — Why Food Choices Matter More on a GLP-1
2:07 How GLP-1 Medications Actually Work
5:17 Protein: Why It's Non-Negotiable
12:44 Carbohydrates: The Fuel You're Still Allowed to Eat
14:40 Healthy Fats: Small Amounts, Real Benefit
15:53 Fiber: The Nutrient That Makes Everything Else Work
20:40 Water: The One Everyone Forgets
23:26 How to Build Your GLP-1 Plate
24:57 Warning Signs: When to Call Your Doctor
26:46 What Realistic Progress Looks Like
27:28 Bringing It All Together
28:41 Resources & Next Steps

References

1. Mozaffarian D, et al. Nutritional priorities to support GLP-1 therapy for obesity. Am J Clin Nutr. 2025.
   https://ajcn.nutrition.org/article/S0002-9165(25)00240-0/fulltext

2. Villareal DT, et al. Weight Loss, Exercise, or Both and Physical Function in Obese Older Adults. NEJM. 2011.
   https://pubmed.ncbi.nlm.nih.gov/21449785/

3. Leidy HJ, et al. Higher protein intake preserves lean mass and satiety with weight loss. Obesity. 2007.
   https://pubmed.ncbi.nlm.nih.gov/17299116/

4. Cruz-Jentoft AJ, et al. Sarcopenia: revised European consensus on definition and diagnosis (EWGSOP2). Age Ageing. 2019.
   https://pmc.ncbi.nlm.nih.gov/articles/PMC6593317/

5. Sacks FM, et al. Comparison of weight-loss diets with different compositions of fat, protein, and carbohydrates. NEJM. 2009.
   https://pubmed.ncbi.nlm.nih.gov/19246357/

6. Johnston BC, et al. Comparison of weight loss among named diet programs in overweight and obese adults. JAMA. 2014.
   https://pubmed.ncbi.nlm.nih.gov/25182101/

7. Rolls BJ. Dietary energy density: applying behavioural science to weight management. Nutr Bull. 2017.
   https://onlinelibrary.wiley.com/doi/abs/10.1111/nbu.12280

8. Estruch R, et al. Primary Prevention of Cardiovascular Disease with a Mediterranean Diet Supplemented with Extra-Virgin Olive Oil or Nuts (PREDIMED). NEJM. 2018.
   https://pubmed.ncbi.nlm.nih.gov/29897866/

9. USDA & HHS. Dietary Guidelines for Americans, 2020-2025.
   https://www.dietaryguidelines.gov/sites/default/files/2020-12/Dietary_Guidelines_for_Americans_2020-2025.pdf

10. American College of Sports Medicine. Position Stand — Resistance Training Prescription for Muscle Function, Hypertrophy, and Physical Performance in Healthy Adults. Med Sci Sports Exerc. 2026.
    https://pubmed.ncbi.nlm.nih.gov/41843416/

11. American Society of Anesthesiologists. Consensus-Based Guidance on Preoperative Management of Patients on GLP-1 Receptor Agonists. 2023.
    https://www.asahq.org/about-asa/newsroom/news-releases/2023/06/american-society-of-anesthesiologists-consensus-based-guidance-on-preoperative

⚕️ MEDICAL & EDUCATIONAL DISCLAIMER
This channel and its content are provided by Dr. Mohammed K. Paika, MD for general educational and informational purposes only. The information presented is not intended as medical advice and does not replace consultation with your personal physician or qualified healthcare professional.
Viewing this content does not create a doctor-patient relationship between you and Dr. Paika.

Dr. Paika and affiliated entities disclaim any liability for injuries, adverse effects, or damages resulting from use or application of information presented in this content.

#Ozempic #Mounjaro #GLP1 #WeightLoss #ObesityMedicine

Ozempic and Mounjaro can be powerful weight-loss tools — but they can also affect your body in ways many people aren't told before starting. In this video, I break down the real risks, the paradox in the trial data, and what to actually watch for.

In this video I walk through why people with type 2 diabetes tend to lose less weight on these medications than people without it, why a meaningful share of the weight lost on GLP-1s can be muscle rather than fat, what the data actually shows about gastroparesis and other GI complications, what happens metabolically when you stop the medication, how bariatric surgery compares, and exactly what to do to protect your muscle and your health if you're on one of these drugs.

Timestamps:
00:00 The risks nobody tells you about
01:12 Who I am, and why this topic keeps me up at night
03:04 The paradox no one is talking about
04:56 Why your brain needs data from your gut
07:01 The detail your prescriber probably never mentioned
09:26 The lesson every doctor should remember
11:21 A quick word before we go further
12:14 The muscle you didn't know you were losing
17:03 When the stomach stops working
20:16 What happens when you stop
21:03 Why bariatric surgery tells a different story
24:11 What to actually do about it
26:30 The bottom line
27:36 Where to go from here

🎓 Complete GLP-1 Weight Loss Masterclass — Lifetime Access
Comprehensive education on GLP-1 medications, nutrition, exercise, muscle preservation, side effects & long-term success. Includes the companion eBook, quizzes, 12-week exercise program, certificate & future course updates at no additional cost.
https://www.drmohammedpaika.com

📩 FREE GLP-1 Diet Cookbook + Weekly Newsletter
Get weekly evidence-based insights on GLP-1s, metabolic health, nutrition, exercise & longevity.
https://www.drmohammedpaika.com/newsletter

📚 The Weight Equation & The Physician’s Physique
Physician-written, evidence-based guides to obesity, weight loss, nutrition, metabolism, exercise, body composition & healthier living.
https://www.drmohammedpaika.com/books

👥 Metabolic Health Community
Live Q&As, evidence-based education, accountability, workouts, nutrition guidance & community support.
https://www.skool.com/metabolic-health-community-5316

👍 Like
💬 Comment
📌 Share
🔔 Subscribe for more honest conversations about obesity, metabolism, hormones, and real-world health solutions

Bohórquez DV, et al. Gut sensor cells & the vagus nerve. Science, 2018. https://doi.org/10.1126/science.aat5236
Holst JJ. The physiology of glucagon-like peptide 1. Physiological Reviews, 2007. https://doi.org/10.1152/physrev.00034.2006
Semaglutide weight loss with vs. without type 2 diabetes — meta-analysis. Pharmaceuticals (Basel), 2025. https://pmc.ncbi.nlm.nih.gov/articles/PMC12300051/
ACCORD Study Group. Effects of intensive glucose lowering in type 2 diabetes. NEJM, 2008. https://www.nejm.org/doi/full/10.1056/NEJMoa0802743
Gamble JM, et al. Insulin dosage and mortality — confounding example. Lancet Diabetes & Endocrinology, 2017. https://doi.org/10.1016/S2213-8587(16)30316-3
Look M, et al. Body composition changes with tirzepatide (SURMOUNT-1). Diabetes, Obesity and Metabolism, 2025. https://doi.org/10.1111/dom.16275
Wilding JPH, et al. Body composition analysis (STEP 1 study). Conference abstract. https://www.newswise.com/pdf_docs/16159288255831_Wilding%20Abstract.pdf
Wilding JPH, et al. Weight regain after stopping semaglutide (STEP 1 extension). Diabetes, Obesity and Metabolism, 2022. https://pmc.ncbi.nlm.nih.gov/articles/PMC9542252/
Sodhi M, et al. GI adverse events with GLP-1 receptor agonists. JAMA, 2023. https://pubmed.ncbi.nlm.nih.gov/37796527/
FDA. Wegovy (semaglutide) prescribing information. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/215256s007lbl.pdf
Obesity Surgery, 2023. https://pubmed.ncbi.nlm.nih.gov/36336720/
Chris Christie's 2013 lap-band surgery. U.S. News & World Report. https://www.usnews.com/news/articles/2013/05/07/chris-christie-admits-to-lap-band-surgery

⚕️ MEDICAL & EDUCATIONAL DISCLAIMER
This channel and its content are provided by Dr. Mohammed K. Paika, MD for general educational and informational purposes only. The information presented is not intended as medical advice and does not replace consultation with your personal physician or qualified healthcare professional. Viewing this content does not create a doctor-patient relationship between you and Dr. Paika.
Dr. Paika and affiliated entities disclaim any liability for injuries, adverse effects, or damages resulting from use or application of information presented in this content.

#Ozempic #Mounjaro #GLP1 #WeightLoss #ObesityMedicine

Some foods can make Ozempic or Mounjaro side effects much worse — even if you're taking the medication exactly as prescribed. In this video, Dr. Mohammed Paika (board-certified in Internal Medicine and Obesity Medicine) breaks down the 5 food categories most likely to cause nausea, reflux, and bloating on a GLP-1 medication — and exactly what to eat instead to support fat loss without fighting your own treatment.

🎓 Complete GLP-1 Weight Loss Masterclass — Lifetime Access
Comprehensive education on GLP-1 medications, nutrition, exercise, muscle preservation, side effects & long-term success. Includes the companion eBook, quizzes, 12-week exercise program, certificate & future course updates at no additional cost.
https://www.drmohammedpaika.com

📩 FREE GLP-1 Diet Cookbook + Weekly Newsletter
Get weekly evidence-based insights on GLP-1s, metabolic health, nutrition, exercise & longevity.
https://www.drmohammedpaika.com/newsletter

📚 The Weight Equation & The Physician’s Physique
Physician-written, evidence-based guides to obesity, weight loss, nutrition, metabolism, exercise, body composition & healthier living.
https://www.drmohammedpaika.com/books

👥 Metabolic Health Community
Live Q&As, evidence-based education, accountability, workouts, nutrition guidance & community support.
https://www.skool.com/metabolic-health-community-5316

Timestamps:
0:00 Hook
0:51 Who I Am & Why This Matters
3:11 Fried & Greasy Foods
6:30 Alcohol
9:37 A Quick Word (GLP-1 Masterclass)
10:54 Easy-to-Overeat Carbs
13:01 Candy & Processed Sweets
15:23 Sugary Drinks
18:54 The Mindset That Actually Works
20:37 End-Screen / Resources

👨‍⚕️ ABOUT DR. MOHAMMED K. PAIKA
Board-Certified in Internal Medicine and Obesity Medicine
Certified Personal Trainer & Nutrition Coach
Helping people understand metabolism, hormones, and sustainable health through evidence-based medicine.

References:
Jelsing et al., 2012, Diabetes Obes Metab — https://pubmed.ncbi.nlm.nih.gov/22226053/
Little et al., 2005, Obes Rev — https://doi.org/10.1111/j.1467-789X.2005.00212.x
Sodhi et al., 2023, JAMA — https://pubmed.ncbi.nlm.nih.gov/37796527/
Suter et al., 1992, N Engl J Med — https://www.nejm.org/doi/full/10.1056/NEJM199204093261503
American Diabetes Association, 2024, Standards of Care — https://diabetesjournals.org/care/issue/47/Supplement_1
Graybiel, 2008, Annu Rev Neurosci — https://pubmed.ncbi.nlm.nih.gov/18558860/
Hall et al., 2019, Cell Metab — https://pubmed.ncbi.nlm.nih.gov/31105044/
Nauck & Meier, 2018, Diabetes Obes Metab — https://pubmed.ncbi.nlm.nih.gov/29364588/
Wilding et al., 2021, N Engl J Med (STEP 1 trial) — https://pubmed.ncbi.nlm.nih.gov/33567185/
McDonald's — Large Sweet Tea nutrition — https://www.mcdonalds.com/us/en-us/product/southern-style-sweet-tea-large.html
Starbucks — Caramel Frappuccino nutrition — https://www.starbucks.com/menu/product-info/?product=caramel-frappuccino-blended-beverage
Volkow, Wang & Baler, 2011, Trends Cogn Sci — https://pubmed.ncbi.nlm.nih.gov/21109477/
DiMeglio & Mattes, 2000, Int J Obes — https://pubmed.ncbi.nlm.nih.gov/10878689/

⚕️ MEDICAL & EDUCATIONAL DISCLAIMER
This channel and its content are provided by Dr. Mohammed K. Paika, MD for general educational and informational purposes only. The information presented is not intended as medical advice and does not replace consultation with your personal physician or qualified healthcare professional.
Viewing this content does not create a doctor-patient relationship between you and Dr. Paika.
Health, nutrition, exercise, and medication topics discussed on this channel may not be appropriate for all individuals. Always consult your own healthcare provider before starting or changing any medication, diet, exercise program, or weight-loss plan, including GLP-1 therapies such as Wegovy, Ozempic, Zepbound, Mounjaro, or similar medications.
Exercise and lifestyle changes carry inherent risks. By choosing to follow any information from this channel, you accept full responsibility for your health decisions and outcomes.
Dr. Paika and affiliated entities disclaim any liability for injuries, adverse effects, or damages resulting from use or application of information presented in this content.

#muscleafter50  #GLP1 #MenOver50Fitness #EvidenceBasedTraining #obesitymedicine 

Building muscle after 50 doesn't work the way it used to — and "just lift heavier" is exactly why most men stay stuck, sore, and stalled. In this video, I break down an evidence-based training framework grounded in NASM's OPT model and backed by ACSM/NSCA resistance-training guidelines for older adults — built to build real muscle while protecting your joints, tendons, and long-term mobility. I also cover why muscle matters even more if you're on a GLP-1 medication, and what the research actually shows about lean mass loss during weight loss.

🎓 Complete GLP-1 Weight Loss Masterclass — Lifetime Access
Comprehensive education on GLP-1 medications, nutrition, exercise, muscle preservation, side effects & long-term success. Includes the companion eBook, quizzes, 12-week exercise program, certificate & future course updates at no additional cost.
https://www.drmohammedpaika.com

📩 FREE GLP-1 Diet Cookbook + Weekly Newsletter
Get weekly evidence-based insights on GLP-1s, metabolic health, nutrition, exercise & longevity.
https://www.drmohammedpaika.com/newsletter

📚 The Weight Equation & The Physician’s Physique
Physician-written, evidence-based guides to obesity, weight loss, nutrition, metabolism, exercise, body composition & healthier living.
https://www.drmohammedpaika.com/books

👥 Metabolic Health Community
Live Q&As, evidence-based education, accountability, workouts, nutrition guidance & community support.
https://www.skool.com/metabolic-health-community-5316

Timestamps
00:00 Intro / The Hook
02:17 Why Your Old Approach Stops Working After 50
05:30 The Science of How Muscle Actually Grows
07:07 The Framework: NASM's OPT Model (Phase 1 & 2)
11:19 What the Exercise-Medicine Guidelines Say (NSCA/ACSM)
13:02 Why This Framework Works Better for Men Over 50
16:02 How to Structure a Chest, Back & Leg Workout
18:51 Advanced Technique: Stacking for More
19:55 Why Muscle Is the Real Longevity Drug
22:14 Your Next Step

References
Schoenfeld (2010) – Mechanisms of Muscle Hypertrophy: https://journals.lww.com/nsca-jscr/fulltext/2010/10000/the_mechanisms_of_muscle_hypertrophy_and_their.40.aspx
Harman et al. – Testosterone Decline, Baltimore Longitudinal Study of Aging: https://pubmed.ncbi.nlm.nih.gov/11158037/
Kubo et al. (2001) – Isometric Training & Tendon Elasticity: https://journals.physiology.org/doi/full/10.1152/jappl.2001.91.1.26
Bohm et al. (2015) – Tendon Adaptation to Mechanical Loading: https://pubmed.ncbi.nlm.nih.gov/27747846/
NASM – The OPT Model: https://www.nasm.org/certified-personal-trainer/the-opt-model
Fragala et al. (2019) – NSCA Resistance Training for Older Adults: https://journals.lww.com/nsca-jscr/fulltext/2019/08000/resistance_training_for_older_adults__position.1.aspx
ACSM (2009) – Progression Models in Resistance Training: https://pubmed.ncbi.nlm.nih.gov/19204579/
Wilding et al. (2021) – STEP 1 Trial (NEJM): https://www.nejm.org/doi/full/10.1056/NEJMoa2032183
Jastreboff et al. – SURMOUNT-1 Body Composition Data: https://pubmed.ncbi.nlm.nih.gov/39996356/

⚠️ MEDICAL & EXERCISE DISCLAIMER
This video is provided for general educational and informational purposes only. It is not intended to provide individualized medical advice, diagnosis, treatment, or exercise prescription and should not be used as a substitute for evaluation or care from your own qualified healthcare professional.

Any medications, treatments, nutrition strategies, supplements, exercises, or other health-related examples discussed in this video are general in nature and may not be appropriate for everyone. Do not start, stop, or change any medication or treatment based solely on information presented in this video. Decisions regarding your health and medical care should be made with your own healthcare professional based on your individual circumstances.

Exercise and physical activity involve inherent risks. Before attempting any exercises shown or discussed, consider your health, fitness level, medical conditions, medications, injuries, physical limitations, balance, and mobility. Exercise within your individual abilities and limitations and use proper form.

Stop exercising if you experience pain, significant discomfort, dizziness, faintness, chest pain, unusual shortness of breath, or other concerning symptoms. If you have an existing medical condition, injury, physical limitation, have been advised to restrict physical activity, or are unsure whether an exercise is appropriate for you, consult your healthcare professional before proceeding.

If you cannot perform an exercise safely or with proper form, do not force the movement. Modify the exercise, choose an appropriate alternative, or avoid it as appropriate for your individual circumstances.

Viewing this video or interacting with its content does not establish a physician-patient relationship.

🎬 STOCK FOOTAGE DISCLOSURE
-Stock media used under license from Storyblocks.

#Ozempic #GLP1 #BrainHealth #WeightLoss #obesitymedicine 

A physician breaks down what Ozempic really does to your brain — benefits, risks, and what the science actually shows.

🎓 Complete GLP-1 Weight Loss Masterclass — Lifetime Access
Comprehensive education on GLP-1 medications, nutrition, exercise, muscle preservation, side effects & long-term success. Includes the companion eBook, quizzes, 12-week exercise program, certificate & future course updates at no additional cost.
https://www.drmohammedpaika.com

📩 FREE GLP-1 Diet Cookbook + Weekly Newsletter
Get weekly evidence-based insights on GLP-1s, metabolic health, nutrition, exercise & longevity.
https://www.drmohammedpaika.com/newsletter

📚 The Weight Equation & The Physician’s Physique
Physician-written, evidence-based guides to obesity, weight loss, nutrition, metabolism, exercise, body composition & healthier living.
https://www.drmohammedpaika.com/books

👥 Metabolic Health Community
Live Q&As, evidence-based education, accountability, workouts, nutrition guidance & community support.
https://www.skool.com/metabolic-health-community-5316

TIMESTAMPS 
00:00 Intro — What Ozempic Really Does to Your Brain
00:54 Who This Is For (and Who I Am)
01:49 How GLP-1 Drugs Talk to Your Brain
03:34 The Whole-Body Domino Effect
04:43 The Immune System Gets a Reset
05:57 Neuroprotection: BDNF, Amyloid & Tau
07:31 Does This Prevent Dementia? The Evidence, Ranked
12:05 Addiction Circuitry: Alcohol, Nicotine & Dopamine
15:40 Psychotic Disorders: Why Not Much Is Expected
16:28 Mood & Anxiety (+ the Jan 2026 FDA Update)
19:02 Eating Disorders: Binge Eating & Bulimia
21:13 Cardiovascular & Stroke Protection
23:22 The Full Picture
24:38 What to Do Next

References
1. Wilding JPH, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). NEJM, 2021. https://pubmed.ncbi.nlm.nih.gov/33567185/
2. Lincoff AM, et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes (SELECT trial). NEJM, 2023. https://pubmed.ncbi.nlm.nih.gov/37952131/
3. Rhea EM, Banks WA. Obesity-induced blood-brain barrier dysfunction: phenotypes and mechanisms. J Neuroinflammation, 2024. https://pmc.ncbi.nlm.nih.gov/articles/PMC11056074/
4. GLP-1 programs the neurovascular landscape. Cell Metabolism, 2024. https://www.cell.com/cell-metabolism/fulltext/S1550-4131(24)00367-X
5. Efficacy and safety of oral semaglutide in early-stage symptomatic Alzheimer's disease (EVOKE/EVOKE+ trials). The Lancet, 2026. https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(26)00459-9/fulltext
6. Wang W, et al. Associations of semaglutide with first-time diagnosis of Alzheimer's disease in patients with type 2 diabetes: target trial emulation using nationwide real-world data in the US. Alzheimer's & Dementia, 2024. https://alz-journals.onlinelibrary.wiley.com/doi/full/10.1002/alz.14313
7. Wang W, Volkow ND, et al. Associations of semaglutide with incidence and recurrence of alcohol use disorder in a real-world population. Nature Communications, 2024. https://www.nature.com/articles/s41467-024-48780-6
8. Hendershot CS, et al. Once-Weekly Semaglutide in Adults With Alcohol Use Disorder: A Randomized Clinical Trial. JAMA Psychiatry, 2025. https://pubmed.ncbi.nlm.nih.gov/39937469/
9. Once-weekly semaglutide vs. placebo in alcohol use disorder and comorbid obesity: RCT. The Lancet, 2026. https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(26)00305-3/fulltext
10. Volkow ND, Xu R. GLP-1R agonist medications for addiction treatment. Addiction, 2025. https://onlinelibrary.wiley.com/doi/10.1111/add.16626
11. FDA Drug Safety Communication: FDA Requests Removal of Suicidal Behavior and Ideation Warning from GLP-1 RA Medications. Jan 13, 2026. https://www.fda.gov/drugs/drug-safety-communications/fda-requests-removal-suicidal-behavior-and-ideation-warning-glucagon-peptide-1-receptor-agonist-glp
12. EMA review finds no link between GLP-1 receptor agonists and suicidal thoughts. April 2024. https://pharmaceutical-journal.com/article/news/ema-finds-no-link-between-glp-1-receptor-agonists-and-suicidal-thoughts
13. Richards J, et al. Successful treatment of binge eating disorder with the GLP-1 agonist semaglutide: a retrospective cohort study. Obesity Pillars, 2023. https://www.sciencedirect.com/science/article/pii/S2667368123000268
14. Fothergill E, et al. Persistent metabolic adaptation 6 years after "The Biggest Loser" competition. Obesity, 2016. https://pubmed.ncbi.nlm.nih.gov/27136388/

⚕️ MEDICAL & EDUCATIONAL DISCLAIMER⚕️ MEDICAL & EDUCATIONAL DISCLAIMER
This content is for general educational and informational purposes only and is not medical advice or a substitute for care from your healthcare provider. Viewing this content does not create a doctor-patient relationship with Dr. Mohammed K. Paika. Always consult your healthcare provider before making changes to medications, diet, exercise, or weight-loss treatment, including GLP-1 therapies. Individual risks and results vary

#Ozempic #Mounjaro #GLP1 #WeightLoss #obesitymedicine 

Ozempic and Mounjaro are two of the most powerful tools we've ever had for weight loss and metabolic health — but what you combine them with matters. In this video, Dr. Mohammed Paika, MD (board-certified in Internal Medicine and Obesity Medicine, hospitalist for nearly 20 years) breaks down 10 medications, substances, and habits that can quietly work against your GLP-1 treatment: SGLT2 inhibitors, metformin, cannabis/THC, artificial sweeteners and sugar alcohols, compounded/gray-market GLP-1 products, skipping resistance training, SSRIs, caffeine, diuretics, and stacking multiple GLP-1 medications. You'll learn the actual physiology behind each risk, real warning signs to watch for, and what to do instead — so your treatment stays safer, easier to stick with, and more effective.

🎓 Complete GLP-1 Weight Loss Masterclass — Lifetime Access
Comprehensive education on GLP-1 medications, nutrition, exercise, muscle preservation, side effects & long-term success. Includes the companion eBook, quizzes, 12-week exercise program, certificate & future course updates at no additional cost.
https://www.drmohammedpaika.com

📩 FREE GLP-1 Diet Cookbook + Weekly Newsletter
Get weekly evidence-based insights on GLP-1s, metabolic health, nutrition, exercise & longevity.
https://www.drmohammedpaika.com/newsletter

📚 The Weight Equation & The Physician’s Physique
Physician-written, evidence-based guides to obesity, weight loss, nutrition, metabolism, exercise, body composition & healthier living.
https://www.drmohammedpaika.com/books

👥 Metabolic Health Community
Live Q&As, evidence-based education, accountability, workouts, nutrition guidance & community support.
https://www.skool.com/metabolic-health-community-5316

Timestamps
0:00 Intro — Why This List Matters
0:42 Meet Dr. Paika + The Ground Rule
1:50 #1 SGLT2 Inhibitors (Euglycemic DKA Risk)
4:34 #2 Metformin
6:59 #3 Cannabis & THC Products
9:12 #4 Artificial Sweeteners & Sugar Alcohols
11:37 Quick Break + Free Resources
13:04 #5 Compounded/Gray-Market GLP-1s
15:25 #6 Skipping Resistance Training
17:57 #7 SSRIs & Serotonergic Medications
20:03 #8 Caffeine
22:12 #9 Diuretics
24:37 #10 Stacking Multiple GLP-1 Medications
26:58 The Bottom Line
27:32 What to Watch Next

Sources & References:
Ozempic (semaglutide) FDA label — https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/209637s035,209637s037lbl.pdf
Mounjaro (tirzepatide) FDA label — https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/215866s041lbl.pdf
SGLT2 inhibitors + GLP-1 → euglycemic DKA — https://pmc.ncbi.nlm.nih.gov/articles/PMC11454998/
Metformin + GLP-1 GI overlap (Diabetes Care) — https://diabetesjournals.org/care/article/47/2/280/153929/
Cannabinoid Hyperemesis Syndrome (StatPearls) — https://www.ncbi.nlm.nih.gov/books/NBK549915/
Sweeteners & gut microbiome (Nature) — https://www.nature.com/articles/nature13793
FDA alert: compounded semaglutide dosing errors — https://www.fda.gov/drugs/human-drug-compounding/fda-alerts-health-care-providers-compounders-and-patients-dosing-errors-associated-compounded
Protein + resistance training for muscle preservation (BJSM) — https://pubmed.ncbi.nlm.nih.gov/28698222/
FDA removes GLP-1 suicidality warning — https://www.fda.gov/drugs/drug-safety-communications/fda-requests-removal-suicidal-behavior-and-ideation-warning-glucagon-peptide-1-receptor-agonist-glp
Caffeine & gastric acid secretion (PNAS) — https://www.pnas.org/doi/10.1073/pnas.1703728114
FDA kidney injury warning, GLP-1-related dehydration — https://healthesystems.com/workerscomprehensive/fda-requires-new-kidney-injury-warning-for-all-glp-1-drugs/
GLP-1/GIP/glucagon receptor pharmacology (tirzepatide, retatrutide) — https://www.nature.com/articles/s41421-024-00700-0

⚕️ MEDICAL & EDUCATIONAL DISCLAIMER⚕️ MEDICAL & EDUCATIONAL DISCLAIMER
This content is for general educational and informational purposes only and is not medical advice or a substitute for care from your healthcare provider. Viewing this content does not create a doctor-patient relationship with Dr. Mohammed K. Paika. Always consult your healthcare provider before making changes to medications, diet, exercise, or weight-loss treatment, including GLP-1 therapies. Individual risks and results vary.

#GLP1 #Ozempic #Wegovy #Mounjaro #WeightLoss

Eating less on Ozempic, Wegovy, Mounjaro, or Zepbound doesn't automatically mean you're eating well. In this video, board-certified Internal Medicine and Obesity Medicine physician Dr. Mohammed Paika breaks down the 10 best foods to eat on a GLP-1 medication — and exactly how they support fat loss, muscle preservation, digestion, and better long-term results from your treatment.

You'll learn how GLP-1 and GIP medications actually work in the body, why muscle loss is the risk nobody warns you about, the exact protein targets to hit every day, and the 10 foods — grouped into muscle-protection, gut-protection, and metabolic-health foods — backed by real clinical research. Plus: the biggest myths about these medications, when a GLP-1 should be avoided, the questions to bring to your own doctor, and simple meal templates you can start using today.

📩 Subscribe to our newsletter for weekly evidence-based insights on GLP-1 science, metabolic health, longevity, nutrition, and healthy recipes. You'll also receive a FREE GLP-1 Diet Cookbook, plus access to our complete resource library, including the GLP-1 Masterclass eBook and my books The Physician's Physique and The Weight Equation:
https://www.drmohammedpaika.com/newsletter

📘 GLP-1 Masterclass Book (PDF):
https://www.drmohammedpaika.com/glp1ebook

🎓 Complete GLP-1 Weight Loss Masterclass (Lifetime Access):
Master the science of sustainable weight loss with comprehensive, evidence-based lessons on GLP-1 medications, nutrition, exercise, muscle preservation, side effect management, and long-term success. Your enrollment includes lifetime access, all future video updates at no additional cost, and 6 months of FREE access to the Metabolic Health Community on Skool.
https://www.drmohammedpaika.com

👥 Join the Metabolic Health Community on Skool for live Q&As, evidence-based education, accountability, expert support, and a supportive community dedicated to improving metabolic health. Follow Dr. Paika's personal workouts, daily cardio routine, nutrition guidance, and healthy habits in real time, ask questions directly, and connect with others committed to achieving lasting metabolic health.
https://www.skool.com/metabolic-health-community-5316

TIMESTAMPS
0:00 Intro – Why "Eating Less" Isn't Enough on a GLP-1
1:48 How GLP-1 & GIP Medications Actually Work
4:18 Why Your Food Choices Matter More Than Ever
6:17 Food #1: Protein (The Non-Negotiable)
9:09 Food #2: Eggs
10:25 Food #3: Oily Fish
11:28 Food #4: Lentils & Beans
13:06 Food #5: Fiber-Rich Vegetables
14:22 Food #6: Kiwifruit
15:41 Food #7: Hydrating Foods & Fluids
17:42 Food #8: Healthy Fats
18:30 Food #9: Greek Yogurt, Cottage Cheese & Skyr
19:20 Food #10: Berries
20:38 Myth vs. Fact
22:21 When to Avoid a GLP-1 Medication
23:06 Questions to Ask Your Doctor
23:38 Simple Meal Templates You Can Start Today
24:30 Final Thoughts + What I'd Watch Next

References
Wilding JPH, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. N Engl J Med. 2021;384(11):989–1002. (STEP 1 trial)
Jastreboff AM, et al. Tirzepatide Once Weekly for the Treatment of Obesity. N Engl J Med. 2022;387(3):205–216. (SURMOUNT-1 trial)
Longland TM, et al. Higher compared with lower dietary protein during an energy deficit combined with intense exercise promotes greater lean mass gain and fat mass loss. Am J Clin Nutr. 2016;103(3):738–746.
Ratliff J, et al. Consuming eggs for breakfast influences plasma glucose and ghrelin, while reducing energy intake during the next 24 h period in adult men. Nutr Res. 2010;30(2):96–103.
Kim SJ, et al. Effects of dietary pulse consumption on body weight: a systematic review and meta-analysis of randomized controlled trials. Am J Clin Nutr. 2016;103(5):1213–1223.
Ha V, et al. Effect of dietary pulse intake on established therapeutic lipid targets for cardiovascular risk reduction. CMAJ. 2014;186(8):E252–E262.
Chan AO, et al. Increasing dietary fiber intake in terms of kiwifruit improves constipation in Chinese patients. World J Gastroenterol. 2007;13(35):4771–4775.
Rush EC, et al. Kiwifruit promotes laxation in the elderly. Asia Pac J Clin Nutr. 2002;11(2):164–168.
Estruch R, et al. Primary Prevention of Cardiovascular Disease with a Mediterranean Diet Supplemented with Extra-Virgin Olive Oil or Nuts. N Engl J Med. 2018;378(25):e34. (PREDIMED)
Mozaffarian D, et al. Changes in Diet and Lifestyle and Long-Term Weight Gain in Women and Men. N Engl J Med. 2011;364(25):2392–2404.

⚕️ MEDICAL & EDUCATIONAL DISCLAIMER
This content is for general educational and informational purposes only and is not medical advice or a substitute for care from your healthcare provider. Viewing this content does not create a doctor-patient relationship with Dr. Mohammed K. Paika. Always consult your healthcare provider before making changes to medications, diet, exercise, or weight-loss treatment, including GLP-1 therapies. Individual risks and results vary.

#GLP1 #Ozempic #wegovy  #WeightLoss #HighProteinDiet

Eating less on Ozempic, Wegovy, Mounjaro, or Zepbound doesn't automatically mean your diet is helping you lose fat. In this video, hospitalist physician Dr. Mohammed Paika breaks down 15 real grocery-aisle swaps — each evaluated for calories, fat, and carbohydrate quality, not just protein — along with the clinical research on why protein and muscle preservation matter so much while you're on a GLP-1.

0:00 Intro — Why "Eating Less" Isn't Enough on a GLP-1 
0:55 Who I Am (Hospitalist Physician, Not an Influencer) 
2:40 The Patient I Think About 
3:53 Why Protein Isn't Optional on a GLP-1 
8:46 15 Swaps: How to Shop Smarter (Start Here) 
10:16 Swap 1: Frozen Peas & Corn vs. Edamame 
10:52 Swap 2: White Rice vs. Lentils 
11:31 Swap 3: Regular Ice Cream vs. High-Protein Ice Cream 
12:16 Swap 4: Breaded Chicken Tenders vs. Tempeh 
12:47 Swap 5: Granola Bar vs. Protein Bar 13:51 Swap 6: Croutons vs. Roasted Chickpeas 14:28 Swap 7: Mayonnaise vs. Hummus 
15:07 Swap 8: Tuna in Oil vs. Tuna in Water 
15:44 Swap 9: Breaded Fried Fish vs. Baked Salmon 
16:23 Swap 10: Fried Chicken vs. Rotisserie Chicken 
16:57 Swap 11: Whole-Milk vs. Part-Skim Mozzarella 
17:27 Swap 12: Regular vs. Powdered Peanut Butter 
18:13 Swap 13: Whole Milk vs. Ultra-Filtered High-Protein Milk 
18:52 Swap 14: Fruit Smoothie vs. Protein Shake 
19:39 Swap 15: All-Beef Tacos vs. Turkey & Black Bean Tacos 
21:59 Why Muscle Is the Organ of Longevity 

📩 Subscribe to our newsletter for weekly evidence-based insights on GLP-1 science, metabolic health, longevity, nutrition, and healthy recipes. You'll also receive a FREE GLP-1 Diet Cookbook, plus access to our complete resource library, including the GLP-1 Masterclass eBook and my books The Physician's Physique and The Weight Equation:
https://www.drmohammedpaika.com/newsletter

📘 GLP-1 Masterclass Book (PDF):
https://www.drmohammedpaika.com/glp1ebook

🎓 Complete GLP-1 Weight Loss Masterclass (Lifetime Access):
Master the science of sustainable weight loss with comprehensive, evidence-based lessons on GLP-1 medications, nutrition, exercise, muscle preservation, side effect management, and long-term success. Your enrollment includes lifetime access, all future video updates at no additional cost, and 6 months of FREE access to the Metabolic Health Community on Skool.
https://www.drmohammedpaika.com

👥 Join the Metabolic Health Community on Skool for live Q&As, evidence-based education, accountability, expert support, and a supportive community dedicated to improving metabolic health. Follow Dr. Paika's personal workouts, daily cardio routine, nutrition guidance, and healthy habits in real time, ask questions directly, and connect with others committed to achieving lasting metabolic health.
https://www.skool.com/metabolic-health-community-5316

References
Look, M., et al. "Body Composition Changes During Weight Reduction with Tirzepatide in the SURMOUNT-1 Study." Diabetes, Obesity and Metabolism, 2025.
Neeland, I.J., et al. "Changes in Lean Body Mass with GLP-1-Based Therapies and Mitigation Strategies." Diabetes, Obesity and Metabolism, 2024.
The Obesity Society. Clinical guidance on protein intake (1.2–1.6 g/kg/day) during active weight loss.
"Higher Protein Intakes Predict Leaner Body Composition in Weight-Loss Participants." International Weight Control Registry, 2024–2025.
"Effects of Varying Protein Amounts and Types on Diet-Induced Thermogenesis: A Systematic Review and Meta-Analysis."
Leidy, H.J., et al. "Effects of Consuming Frequent, Higher Protein Meals on Appetite and Satiety During Weight Loss in Overweight/Obese Men." Obesity (Silver Spring), 2011.
"Dietary Recommendations for the Management of Gastrointestinal Symptoms in Patients Treated with GLP-1 Receptor Agonists."
"Clinical Recommendations to Manage Gastrointestinal Adverse Events in Patients Treated with GLP-1 Receptor Agonists: A Multidisciplinary Expert Consensus."
Leong, D.P., et al. "Prognostic Value of Grip Strength: Findings from the PURE Study." The Lancet, 2015;386(9990):266–273.
"Lean Mass and Musculoskeletal Preservation in GLP-1-Based Obesity Treatment: Nutrition, Exercise, Supplementation, and Monitoring Strategies." 2025.
Tinsley, G.M., Nadolsky, S. "Preservation of Lean Soft Tissue During Weight Loss Induced by GLP-1 and GLP-1/GIP Receptor Agonists: A Case Series." 2025.
LEAN-PREP Study Protocol: Resistance Exercise and Protein During Semaglutide/Tirzepatide Therapy.

⚕️ MEDICAL & EDUCATIONAL DISCLAIMER
This channel and its content are provided by Dr. Mohammed K. Paika, MD for general educational and informational purposes only. The information presented is not intended as medical advice and does not replace consultation with your personal physician or qualified healthcare professional. Dr. Paika and affiliated entities disclaim any liability for injuries, adverse effects, or damages resulting from use or application of information presented in this content.

#Ozempic #GLP1 #WeightLossJourney #ObesityMedicine #semaglutideforweightloss 

You can be taking Ozempic every week and still stall out — not because the medication stopped working, but because of habits that quietly cancel it out. In this video, Dr. Mohammed Paika (board-certified in Internal Medicine and Obesity Medicine) breaks down the 10 most common mistakes that stall fat loss, cost muscle, and cause GLP-1 side effects — and exactly what to do instead.

📩 Subscribe to our newsletter for weekly evidence-based insights on GLP-1 science, metabolic health, longevity, nutrition, and healthy recipes. You'll also receive a FREE GLP-1 Diet Cookbook, plus access to our complete resource library, including the GLP-1 Masterclass eBook and our books *The Physician's Physique* and *The Weight Equation*:
https://www.drmohammedpaika.com/newsletter

📘 GLP-1 Masterclass Book (PDF):
https://www.drmohammedpaika.com/glp1ebook

🎓 Complete GLP-1 Weight Loss Masterclass:
https://www.drmohammedpaika.com

👥 Join the Metabolic Health Community on Skool for live Q&As, evidence-based education, accountability, expert support, and a community of people committed to improving their metabolic health:
https://www.skool.com/metabolic-health-community-5316

TIMESTAMPS
00:00 – Intro: why "it stopped working" is usually the wrong diagnosis
01:52 – How GLP-1 medications actually work
03:48 – Mistake #1: Out-dieting the medication
06:02 – Mistake #2: Letting protein become optional
08:41 – Mistake #3: Skipping resistance training
11:04 – Mistake #4: Letting daily movement quietly disappear
14:04 – Mistake #5: Eating heavy combo meals like nothing changed
15:43 – Mistake #6: Getting dehydrated
17:09 – Mistake #7: Drinking your calories
19:08 – Mistake #8: Using the scale as your only scoreboard
21:02 – Mistake #9: Freestyling your dosing
22:57 – Mistake #10: Injecting the same spot every time
24:17 – Full recap
25:13 – Final thoughts + next steps

👨‍⚕️ ABOUT DR. MOHAMMED K. PAIKA
Board-Certified in Internal Medicine and Obesity Medicine
Certified Personal Trainer & Nutrition Coach
Helping people understand metabolism, hormones, and sustainable health through evidence-based medicine.

👍 Like
💬 Comment
📌 Share
🔔 Subscribe for more honest conversations about obesity, metabolism, hormones, and real-world health solutions

References

Wilding et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1), NEJM 2021 — nejm.org/doi/full/10.1056/NEJMoa2032183
Jastreboff et al. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1), NEJM 2022 — nejm.org/doi/abs/10.1056/NEJMoa2206038
Lincoff et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes (SELECT), NEJM 2023 — pubmed.ncbi.nlm.nih.gov/37952131
Neeland et al. Changes in Lean Body Mass with GLP-1-Based Therapies and Mitigation Strategies, Diabetes Obes Metab 2024 — pubmed.ncbi.nlm.nih.gov/38937282
Enhanced Protein Intake on Maintaining Muscle Mass, Strength, and Physical Function in Adults with Overweight/Obesity (meta-analysis) — pmc.ncbi.nlm.nih.gov/articles/PMC8978023

⚕️ MEDICAL & EDUCATIONAL DISCLAIMER
This channel and its content are provided by Dr. Mohammed K. Paika, MD for general educational and informational purposes only. The information presented is not intended as medical advice and does not replace consultation with your personal physician or qualified healthcare professional. Viewing this content does not create a doctor-patient relationship between you and Dr. Paika.Health, nutrition, exercise, and medication topics discussed on this channel may not be appropriate for all individuals. Always consult your own healthcare provider before starting or changing any medication, diet, exercise program, or weight-loss plan, including GLP-1 therapies such as Wegovy, Ozempic, Zepbound, Mounjaro, or similar medications. Exercise and lifestyle changes carry inherent risks. By choosing to follow any information from this channel, you accept full responsibility for your health decisions and outcomes. Dr. Paika and affiliated entities disclaim any liability for injuries, adverse effects, or damages resulting from use or application of information presented in this content.